Hosted by IntegriChain, the conference serves as a specialized forum for market access, finance, and commercial leaders. The current surge in interest reflects an industry grappling with heightened policy volatility and intense pressure on drug pricing. According to Josh Halpern, CEO of IntegriChain, manufacturers are prioritizing the event to bridge the gap between policy, pricing, and operational execution, moving away from traditional departmental silos.

To maintain the caliber of discourse, organizers intentionally cap attendance. Bill Roth, SVP of Consulting & Advisory, noted that the firm will not expand capacity once the threshold is reached. The 2026 agenda includes sessions tailored to varying manufacturer sizes and portfolio models, supported by sponsors such as GiftHealth, PHIL, Medfuse, Courier Health, and BioCareSD. Interested parties are being urged to finalize their registration through the official portal before the final seats are exhausted.